

830 **Supporting Information**

831 **Engineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal**  
832 **Remodeling of Tumors**

833

834 *Shindu C. Thomas, Tushar Madaan, Nitin S. Kamble, Nabil A. Siddiqui, Giovanni M. Pauletti,*  
835 *Nalinikanth Kotagiri\**

836

837 S. C. Thomas, T Madaan, Dr. N. S. Kamble, N. Siddiqui, Prof. Nalinikanth Kotagiri

838 Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy,

839 University of Cincinnati, 231 Albert Sabin Way,

840 Cincinnati, OH 45267, USA

841 Email id: [kotaginh@ucmail.uc.edu](mailto:kotaginh@ucmail.uc.edu)

842



843 Prof. Giovanni M. Pauletti,

844 Department of Pharmaceutical and Administrative Sciences,

845 University of Health Sciences and Pharmacy in St. Louis, 1 Pharmacy Place


846 St. Louis, MO 63110, USA

847



848

849 **Supplementary Figure S1:** (A) Schematic showing deletion of *nlpI* gene using homologous  
 850 recombination. (B) Colony PCR results showing the presence of the amplified chloramphenicol  
 851 from the  $\Delta E$  colonies (500bp).




852

853 **Supplementary Figure S2:** Design of the expression plasmid: *pecol19A-ClyA-Hy*.

854


855



856

857 **Supplementary Figure S3:  $\Delta$ ECHy and EcN growth curve (Optical Density at 600nm vs time**  
858 **(hours)**


859



860


861 **Supplementary Figure S4:** IHC analysis of tumor tissues showing abundant extracellular

862 macromolecules: HA, Fibronectin, Periostin and Collagen IV (x400 magnification).



863  
 864 **Supplementary Figure S5:** Line graphs showing tumor progression in mice with 4T1 tumors for  
 865 each treatment group tested.

866



867


868 **Supplementary Figure S6: 4T1-IHC marker quantification for different treatment groups (A)**

869 HA and SMA (B) CC3 and Ki67. (\*\*\*\* for  $p < 0.0001$ , \*\*\*for  $p < 0.001$ , \*\* for  $p < 0.01$ )

870

871

872



873

874 **Supplementary Figure S7:** Line graphs showing tumor progression in mice with MC38 tumors  
875 for each treatment group tested.

876

877


878

879

880



881




882

883 **Supplementary Figure S8: MC38-IHC marker quantification for different treatment groups (A)**

884 HA and SMA (B) CC3, Ki67 and CD8. (\*\*\*\* for  $p < 0.0001$ , \*\*\* for  $p < 0.001$ , \*\* for  $p < 0.01$ )

885

886



888

889 **Supplementary Figure S9:** Proteome profiling for studying the regulation of different cytokines  
 890 and chemokines in mice (plasma). **(A)** Representative diagram for the location of different spots  
 891 representing cytokine specific antibodies. **(B)** Spots developed on the nitrocellulose membrane  
 892 for each group tested.

893